S21 Stock Overview
Develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
S2Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0008 |
| 52 Week High | SEK 0.011 |
| 52 Week Low | SEK 0.0001 |
| Beta | 0.84 |
| 1 Month Change | 14.29% |
| 3 Month Change | -63.64% |
| 1 Year Change | -91.11% |
| 3 Year Change | -99.84% |
| 5 Year Change | -99.91% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| S21 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -11.1% | -0.1% | 1.2% |
| 1Y | -91.1% | -9.1% | 10.1% |
Return vs Industry: S21 underperformed the German Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: S21 underperformed the German Market which returned 9.4% over the past year.
Price Volatility
| S21 volatility | |
|---|---|
| S21 Average Weekly Movement | 175.4% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S21's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: S21's weekly volatility has decreased from 249% to 175% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 17 | Petter Sivlér | www.s2m.se |
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. It offers Epiprotect 2117, a synthetic allograft/xenograft substitute; Epiprotect Ulcer, a wound dressing consisting of a thin film of biosynthetic cellulose polymer intended to be used as a protective barrier for superficial wounds and deep wounds that have breached the dermis, as well as used as a temporary coverage for deep extensive wounds before transplantation or other surgical intervention. The company also provides washable, durable, waterproof, and self-adhesive bandages under the INSTABIND brand name, as well as NO SMELL, a perfume-free odour remover.
S2Medical AB (publ) Fundamentals Summary
| S21 fundamental statistics | |
|---|---|
| Market cap | €238.29k |
| Earnings (TTM) | -€161.88k |
| Revenue (TTM) | €956.88k |
0.2x
P/S Ratio-1.5x
P/E RatioIs S21 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S21 income statement (TTM) | |
|---|---|
| Revenue | SEK 10.99m |
| Cost of Revenue | SEK 1.54m |
| Gross Profit | SEK 9.45m |
| Other Expenses | SEK 11.31m |
| Earnings | -SEK 1.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0065 |
| Gross Margin | 85.99% |
| Net Profit Margin | -16.92% |
| Debt/Equity Ratio | 0% |
How did S21 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 04:43 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
S2Medical AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|